 |
Marc Tessier-Lavigne
President
The Rockefeller University |
MODERATOR |
Barry Coller, M.D.
Vice President for Medical
Affairs and
Physician-in-Chief
The Rockefeller University
Director
Center for Clinical and
Translational Science
|
|
CO-CHAIRS |
Anthony B. Evnin, Ph.D.
General Partner
Venrock |
Robin Chemers Neustein
Senior Director
Goldman, Sachs & Co.
|
|
STEERING COMMITTEE |
|
Ron Cohen, M.D.
Acorda Therapeutics |
Kathleen Denis, Ph.D.
The Rockefeller University |
David Elliman
Elmrock Capital |
Emilio Emini, Ph.D.
Pfizer |
Teena Lerner, Ph.D.
Rx Capital Management |
Paul Maddon, M.D., Ph.D.
Progenics Pharmaceuticals |
Brad Margus
Envoy Therapeutics |
Sharon Mates, Ph.D.
Intra-Cellular Therapies |
Robin Chemers Neustein
Goldman, Sachs & Co. |
Russell Pennoyer
Benedetto, Gartland & Co. |
Geoff Smith
Ascent Biomedical Ventures |
George Yancopoulos,
M.D., Ph.D.
Regeneron Pharmaceuticals
|
|
|
CONTACT |
bridges@rockefeller.edu |
|
Bridges to Better Medicine brings together world class scientists and business leaders in the life sciences - venture capitalists, biotechnology and pharmaceutical executives, healthcare investors and analysts. The Rockefeller University believes that fostering a robust intellectual exchange between academia and industry is critical to advancing biomedical breakthroughs.
Bridges offers you opportunities to:
- hear about the latest scientific and medical innovations from inside the lab and from industry;
- interact with top scientists and industry leaders in a private setting;
- develop valuable relationships and exchange ideas with peers.
Through this program, The Rockefeller University hopes to develop
friendships and inspire philanthropy among individuals in life
science-related businesses.
to become a member |
**********************
A Scientific Symposium in Memory of
Ralph M. Steinman
Monday, May 14, 2012
The Rockefeller University gratefully acknowledges the following sponsors of the Steinman Memorial Symposium:
Gold:
Silver:
|
|
UPCOMING EVENTS |
Monday, May 14, 2012
8:30 a.m. - 5:30 p.m.
Caspary Auditorium
The Rockefeller University
1230 York Avenue (at East 66th Street)
New York City
For
more information on sponsorship opportunities, please contact Cliff
Wasser, Director of Bridges to Better Medicine, at 212-327-8966 or cwasser@rockefeller.edu.
To RSVP, click here or contact Arianne Dowdell, Communications & Public Affairs, at 212-327-8073 or adowdell@rockefeller.edu.
*********
May 23, 2012 6:00 p.m. - 7:30 p.m. Caspary Auditorium The Rockefeller University 1230 York Avenue (at East 66th Street) New York City Speaker Paul Greengard, Ph.D.Vincent Astor Professor Head, Laboratory of Molecular and Cellular Neuroscience The Rockefeller University
|
|
If you have questions, or would like to make suggestions for future programs, please call (212) 327-8910 or email bridges@rockefeller.edu. |
|
April 20, 2012
Rockefeller creates Cohn-Steinman Professorship to honor discoverers of dendritic cells
The family of the late Ralph Steinman, who died three days
before winning the Nobel Prize, will donate much of the proceeds from
the award to establish the Cohn-Steinman Professorship at Rockefeller. The professorship will create an enduring
memorial to Steinman and his mentor and collaborator, Zanvil Cohn. |
March 21, 2012
Albany Medical Center Prize awarded to James E. Darnell, Jr. and Robert G. Roeder
Darnell and Roeder are being recognized for helping to define how cells grow, replicate, and become specialized, and in turn giving medical professionals and researchers the tools to improve health and combat diseases. |
February 27, 2012
$15 million gift from Helmsley Trust to fund research on digestive diseases
Funds will establish a new center, to be known as the Center for Basic
and Translational Research on Disorders of the Digestive System, which
will support interdisciplinary basic research and foster collaborations
among some 20 Rockefeller labs. |
December 16, 2011
In cancer, molecular signals that recruit blood vessels also trigger metastasis
Cancer cells are most deadly when they’re on the move. New research has now shown how a miRNA prevents the recruitment and
formation of blood vessels near cancer cells destined to become
metastases. |
November 17, 2011
Statin-intolerant patients need a different type of clinical trial
Although only 5% of people in clinical trials report side effects from statin drugs, in practice the problem is far greater. Clinical trials need to better address the needs of statin-intolerant patients, Rockefeller researchers say. |
|
|
Read More; |
|
